Drug Profile


Alternative Names: BAY-853934; HIF-PH; HIF-PH inhibitor - Bayer; Hypoxia-inducible factor-prolyl hydroxylase inhibitor - Bayer

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Antianaemics; Morpholines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Bayer completes the DIALOGUE 3 trial in Anaemia (Associated with chronic renal failure) in Australia, Bulgaria, France, Germany, Hungary, Israel, Italy, Japan, South Korea, Poland, Romania, Spain, Turkey and United Kingdom (NCT02055482)
  • 01 Dec 2016 Bayer initiates enrolment in the DIALOGUE 3 trial for Anaemia (Associated with chronic renal failure) in Australia, France, Israel, South Korea, Poland, Romania and Turkey (NCT02055482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top